MX9204229A - Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis. - Google Patents

Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis.

Info

Publication number
MX9204229A
MX9204229A MX9204229A MX9204229A MX9204229A MX 9204229 A MX9204229 A MX 9204229A MX 9204229 A MX9204229 A MX 9204229A MX 9204229 A MX9204229 A MX 9204229A MX 9204229 A MX9204229 A MX 9204229A
Authority
MX
Mexico
Prior art keywords
trifluorometilbencilfosfonatos
osteoporosis
useful
treatment
trifluorometilbencilfosfonatos useful
Prior art date
Application number
MX9204229A
Other languages
English (en)
Spanish (es)
Inventor
Charles Schwender
Keith Demarest
David Wustrow
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MX9204229A publication Critical patent/MX9204229A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882Arylalkanephosphonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056Esters of arylalkanephosphonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9204229A 1991-07-18 1992-07-17 Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis. MX9204229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/732,267 US5300687A (en) 1991-07-18 1991-07-18 Trifluoromethylbenzylphosphonates useful in treating osteoporosis

Publications (1)

Publication Number Publication Date
MX9204229A true MX9204229A (es) 1993-04-01

Family

ID=24942866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9204229A MX9204229A (es) 1991-07-18 1992-07-17 Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis.

Country Status (14)

Country Link
US (2) US5300687A (enExample)
EP (1) EP0524023A1 (enExample)
JP (1) JPH05213977A (enExample)
KR (1) KR930002364A (enExample)
CN (1) CN1070408A (enExample)
AU (1) AU657146B2 (enExample)
CA (1) CA2074020A1 (enExample)
FI (1) FI923289A7 (enExample)
HU (1) HUT62907A (enExample)
IE (1) IE922341A1 (enExample)
MX (1) MX9204229A (enExample)
NO (1) NO922851L (enExample)
TW (1) TW216796B (enExample)
ZA (1) ZA925391B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
ZA941088B (en) * 1993-02-19 1995-09-27 Symphar Sa Substituted ketophosphonates the processes for their preparation and pharmaceutical compositions containing them
DE69412538T2 (de) * 1993-05-18 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Benzopyran-Derivate und ihre Verwendung
CN1151744A (zh) * 1994-07-04 1997-06-11 武田药品工业株式会社 膦酸化合物及其制备和应用
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6911553B1 (en) 1997-10-02 2005-06-28 Roche Diagnostics Gmbh Osteoblast-specific mitogens and drugs containing such compounds
EP0906759A1 (de) 1997-10-02 1999-04-07 Roche Diagnostics GmbH Neue Osteoblastenspezifische Mitogene: Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
WO2000028982A2 (en) 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20020150887A1 (en) * 2000-11-09 2002-10-17 National Institute Of Advanced Industrial Science And Technology Methods and nucleic acid probes for molecular genetic analysis of polluted environments and environmental samples
US20050032060A1 (en) * 2001-08-31 2005-02-10 Shishir Shah Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
JP2005519634A (ja) 2001-10-12 2005-07-07 スペクトラル ジェノミクス、インク. 核酸組成物及びアレイ及びそれらを用いる方法
US7439346B2 (en) * 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
US6916621B2 (en) * 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
EP1622623A4 (en) * 2003-04-11 2009-03-18 Barr Lab Inc METHOD FOR THE ADMINISTRATION OF ESTROGENIC AND TESTED
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8821884B2 (en) * 2004-07-27 2014-09-02 The Regents Of The University Of California Compositions and methods using MD-2 mutants and chimeric proteins
CN1302001C (zh) * 2005-01-20 2007-02-28 申厚宝 邻氯苄基膦酸二甲酯生产工艺
WO2006110656A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US20100221345A1 (en) 2006-01-18 2010-09-02 National University Corporation Tokyo Medical And Osteogenic biomaterial containing osteogenesis promoting substance and nanogel
ES2393815T3 (es) 2007-03-30 2012-12-28 Tioga Pharmaceuticals, Inc. Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante
ES2572631T3 (es) * 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
WO2010007081A1 (en) 2008-07-18 2010-01-21 Georgia Tech Research Corporation Stable electrodes with modified work functions and methods for organic electronic devices
US8609371B2 (en) * 2008-08-12 2013-12-17 Allylix, Inc. Isoprenoid compounds
SI2326720T1 (en) 2008-09-15 2018-06-29 F. Hoffmann-La Roche Ag Substances and procedures for regulating cellular osmolality
JP5350733B2 (ja) * 2008-09-30 2013-11-27 株式会社クレハ ホスホン酸、ホスホン酸銅化合物、樹脂組成物及び積層体
JP5699127B2 (ja) 2009-04-06 2015-04-08 ジョージア・テック・リサーチ・コーポレーション 新規なホスホン酸表面改質剤を含む電子デバイス
US7960456B2 (en) 2009-05-27 2011-06-14 Bromine Compounds Ltd. Halogenated phosphonates, processes for their preparation and their use as flame retardants
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US20120164104A1 (en) 2009-08-03 2012-06-28 Chimerix, Inc. Composition and Methods of Treating Viral Infections and Viral Induced Tumors
PL2534150T3 (pl) 2010-02-12 2017-09-29 Chimerix, Inc. Sposoby leczenia infekcji wirusowej
AU2011248620B2 (en) 2010-04-26 2015-11-26 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP4174077A1 (en) * 2021-10-27 2023-05-03 Merck Patent GmbH Electronic switching device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917533A (en) * 1954-05-12 1959-12-15 Virginia Carolina Chem Corp Dialkylaminoalkyl esters of phosphonic acid and method of preparing same
US3363032A (en) * 1964-06-11 1968-01-09 Monsanto Co Long chain aliphatic benzylphosphonic acids, esters and salts
DE3339383A1 (de) * 1983-10-29 1985-05-09 Bayer Ag, 5090 Leverkusen Distyrylverbindungen
US4822780A (en) * 1987-07-08 1989-04-18 Otsuka Pharmaceutical Factory, Inc. Carboxamide compounds
DE4003054A1 (de) * 1990-02-02 1991-08-08 Hoechst Ag Verwendung von benzylphosphonsaeurederivaten zur behandlung von durch viren verursachte krankheiten
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis

Also Published As

Publication number Publication date
FI923289L (fi) 1993-01-19
AU1965692A (en) 1993-01-21
FI923289A7 (fi) 1993-01-19
JPH05213977A (ja) 1993-08-24
FI923289A0 (fi) 1992-07-17
IE922341A1 (en) 1993-01-27
TW216796B (enExample) 1993-12-01
US5300687A (en) 1994-04-05
CN1070408A (zh) 1993-03-31
HUT62907A (en) 1993-06-28
ZA925391B (en) 1994-01-17
KR930002364A (ko) 1993-02-23
NO922851D0 (no) 1992-07-17
AU657146B2 (en) 1995-03-02
CA2074020A1 (en) 1993-01-19
NO922851L (no) 1993-01-19
EP0524023A1 (en) 1993-01-20
HU9202353D0 (en) 1992-10-28
US5532226A (en) 1996-07-02

Similar Documents

Publication Publication Date Title
MX9204229A (es) Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis.
DE69203471D1 (de) Brausendes Bademittel.
FI910167L (fi) Manuell massageapparat.
DE69203428D1 (de) Verbinder.
DE69418007D1 (de) Behandlungsbehälter
FR2677243B1 (fr) Appareillage orthopedique dento-facial.
FI914409L (fi) Kalciumupptagande inhibitorer.
DE69410520D1 (de) Behandlungsbehälter
FI913256A0 (fi) En generell synkronisk 2n+1 -divisor.
EP0639331A3 (en) Fumigants.
DE69203171D1 (de) Verbinder.
FI914408L (fi) Kalciumupptagande inhibitorer.
DE69206522D1 (de) Vibrator.
DE59200147D1 (de) Verbundstein bzw. Verbundplatte.
FI912080A0 (fi) Lagringslaoda foersedd med en gavelvaeggen slutande genomsynlig klaffskiva.
FI914410L (fi) Kalciumupptagande inhibitorer.
FI914904L (fi) Ortopedisk raetningsspjaela
DE69203364D1 (de) Verbinder.
FR2697998B1 (fr) Chevillère.
DE69201785D1 (de) Verbinder.
FI920701A0 (fi) Anordning foer terapeutisk tryck- behandling.
FI921634A0 (fi) Med elkraft el producerande kraftverk och -maskin.
FI910355A7 (fi) Massageanlaeggning.
KR930006250U (ko) 지압기
ES1017890Y (es) Dispositivo para el tratamiento de uneros.